rs772766102
Positions:
Variant summary
Our verdict is Benign. Variant got -15 ACMG points: 1P and 16B. PM4_SupportingBP6_Very_StrongBS1BS2
The NM_001099922.3(ALG13):βc.2383_2385delβ(p.Glu795del) variant causes a inframe deletion change. The variant allele was found at a frequency of 0.000907 in 1,208,532 control chromosomes in the GnomAD database, including 1 homozygotes. There are 330 hemizygotes in GnomAD. Variant has been reported in ClinVar as Likely benign (β β ).
Frequency
Genomes: π 0.00060 ( 0 hom., 18 hem., cov: 23)
Exomes π: 0.00094 ( 1 hom. 312 hem. )
Consequence
ALG13
NM_001099922.3 inframe_deletion
NM_001099922.3 inframe_deletion
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 4.48
Genes affected
ALG13 (HGNC:30881): (ALG13 UDP-N-acetylglucosaminyltransferase subunit) The protein encoded by this gene is a subunit of a bipartite UDP-N-acetylglucosamine transferase. It heterodimerizes with asparagine-linked glycosylation 14 homolog to form a functional UDP-GlcNAc glycosyltransferase that catalyzes the second sugar addition of the highly conserved oligosaccharide precursor in endoplasmic reticulum N-linked glycosylation. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -15 ACMG points.
PM4
Nonframeshift variant in NON repetitive region in NM_001099922.3. Strenght limited to Supporting due to length of the change: 1aa.
BP6
Variant X-111730405-TGAA-T is Benign according to our data. Variant chrX-111730405-TGAA-T is described in ClinVar as [Likely_benign]. Clinvar id is 412613.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-111730405-TGAA-T is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.000604 (68/112490) while in subpopulation NFE AF= 0.000976 (52/53284). AF 95% confidence interval is 0.000764. There are 0 homozygotes in gnomad4. There are 18 alleles in male gnomad4 subpopulation. Median coverage is 23. This position pass quality control queck.
BS2
High Hemizygotes in GnomAd4 at 18 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ALG13 | NM_001099922.3 | c.2383_2385del | p.Glu795del | inframe_deletion | 20/27 | ENST00000394780.8 | NP_001093392.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALG13 | ENST00000394780.8 | c.2383_2385del | p.Glu795del | inframe_deletion | 20/27 | 2 | NM_001099922.3 | ENSP00000378260 | A2 |
Frequencies
GnomAD3 genomes AF: 0.000604 AC: 68AN: 112490Hom.: 0 Cov.: 23 AF XY: 0.000519 AC XY: 18AN XY: 34654
GnomAD3 genomes
AF:
AC:
68
AN:
112490
Hom.:
Cov.:
23
AF XY:
AC XY:
18
AN XY:
34654
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000439 AC: 78AN: 177526Hom.: 0 AF XY: 0.000366 AC XY: 24AN XY: 65508
GnomAD3 exomes
AF:
AC:
78
AN:
177526
Hom.:
AF XY:
AC XY:
24
AN XY:
65508
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000938 AC: 1028AN: 1096042Hom.: 1 AF XY: 0.000863 AC XY: 312AN XY: 361688
GnomAD4 exome
AF:
AC:
1028
AN:
1096042
Hom.:
AF XY:
AC XY:
312
AN XY:
361688
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000604 AC: 68AN: 112490Hom.: 0 Cov.: 23 AF XY: 0.000519 AC XY: 18AN XY: 34654
GnomAD4 genome
AF:
AC:
68
AN:
112490
Hom.:
Cov.:
23
AF XY:
AC XY:
18
AN XY:
34654
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:7
Benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jan 03, 2018 | - - |
Likely benign, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Likely benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2022 | ALG13: BS2 - |
Likely benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Sep 16, 2022 | See Variant Classification Assertion Criteria. - |
Developmental and epileptic encephalopathy, 36 Benign:2
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Dec 05, 2021 | - - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 30, 2017 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
ALG13-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 25, 2024 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at